

Do we need meshes in pelvic floor reconstruction?

Kaven Baessler

Received: 24 October 2011 / Accepted: 29 October 2011 / Published online: 16 November 2011
© Springer-Verlag 2011

Abstract

Objectives Transvaginally placed mesh in pelvic reconstructive surgery for women with pelvic organ prolapse has gained popularity because of excellent anatomical outcomes, but postoperative mesh-related complications have lead to a number of cautious reviews and warnings. This review focuses on functional outcomes after synthetic transvaginal mesh placement.

Methods MEDLINE database was searched from 2010 to August 2011 for original articles on transvaginal mesh surgery for pelvic organ prolapse not included in recent reviews. The following search terms were used: pelvic organ prolapse, genital prolapse, cystocele, rectocele and mesh, synthetic graft, and repair. Studies were assessed and appropriate data extracted and tabularized. Studies were excluded if the follow-up time was less than 12 months and if studies did not contain original data or data on subjective outcome.

Results Eleven studies irregularly reported functional outcomes. After trocar-guided transobturator vaginal mesh surgery, symptomatic recurrence of pelvic organ prolapse was reported between 7 and 33%. If analyzed cumulatively, 76 of 370 patients (21%) complained of prolapse symptoms postoperatively. De novo stress urinary incontinence occurred in 12–17% and persisted in up to 68% after trocar-guided mesh surgery. De novo dyspareunia was present between 2 and 15%, worsened or de novo dyspareunia between 25 and 44%. Deteriorating coital incontinence was described in 6 of 16 women after anterior Prolift in one trial.

Conclusions When counseling women for pelvic reconstructive surgery, we should provide them with evidence-based information on functional outcomes and subsequently take the patient's concerns and preferences into account. Pelvic floor symptoms were scarcely reported in reviewed trials, but demonstrated a worse scenario than anatomical outcomes.

Keywords Pelvic organ prolapse · Pelvic reconstructive surgery · Pelvic floor symptoms and function · Quality of life · Mesh

Introduction

Do we need meshes in pelvic floor reconstruction? The answer is 'Yes', we need meshes, but not in every patient, not routinely. Not many people will argue about the enormous advantages the development of synthetic mid-urethral slings have brought to patients (and surgeons and industry); not even the success of synthetic mesh in abdominal sacrocolpopexies is doubted. The partially public and arduous dispute is more on the value of mesh in vaginal pelvic floor surgery, as many complications or problems are caused by the vaginally placed mesh to treat pelvic organ prolapse. The most recent FDA notification emphasizes to cautiously employ vaginal meshes in likely to be beneficial circumstances (<http://www.fda.gov/cdrh/safety/102008-surgicalmesh.html>). Most mesh erosions are not serious, and many do not require a surgical intervention. However, there are no studies investigating the patients view and quality of life regarding mesh erosion symptoms, re-operations to trim mesh, and oversewing. Therefore, we can only say that many surgeons do not consider these complications serious. Intractable pain

K. Baessler (✉)

Pelvic Floor Unit Charité Universitätsmedizin Berlin,
Hindenburgdamm 30, 12203 Berlin, Germany
e-mail: Kaven.baessler@charite.de

syndromes, however, are serious and further surgery may be difficult, complicated, and unsuccessful. Now the FDA has again informed the public about risks of vaginal mesh procedures, has asked health care providers to be cautious, and also makes them responsible for indications, appropriate counseling, and surgery of the patients. Although industry should provide scientific evidence to support the use of their mesh, the clinician has to ensure that the correct procedure and material has been selected, that the operation can be performed with a high standard, that the patient has been informed and counseled according to her needs and abilities, and that an audit is in place.

There is no scarcity of current reviews on the use of mesh for pelvic organ prolapse repair [1–17]. Conclusions of recent reviews are relatively consistent: Although there is now evidence to use mesh in the anterior compartment, long-term efficacy and safety are not known, and data on pelvic floor function is limited. Surgeons should carefully select patients and procedures and above all should adequately counsel patients.

While it is known that anatomical success does not necessarily correlate with functional outcome, we operate on patients with POP because of their symptomatic pelvic organ support defects. We repair these defects and restore anatomy, while hopefully restoring or maintaining function as well. Restored anatomy deems an operation successful, and it is unlikely that a woman with stage 0 or 1 will have typical prolapse symptoms like prolapse sensation or feeling a bulge [18]. On the contrary, she might not be aware of a prolapse stage 2 [18]. Certainly, for a surgeon, it is comforting to look at a patient complaining of lower urinary tract symptoms postoperatively when she has no recurrent prolapse.

The following review will focus on functional outcomes like prolapse symptoms (subjective outcome), stress urinary incontinence, overactive bladder, voiding difficulties, bowel function, and dyspareunia, as well as on advantages and disadvantages, evidence and eminence, and aptitudes and attitudes with regard to synthetic transvaginal mesh placement in urogynecology and pelvic floor reconstructive surgery. Examples for changes in the decision-making process are given.

Methods

Given the existing reviews covering studies partially up to 2010, the MEDLINE database was searched from 2010 to August 2011 for original articles not included in these reviews with the following keywords: pelvic organ prolapse, genital prolapse, cystocele, rectocele and mesh, synthetic graft, and repair. Studies were assessed and appropriate data extracted and tabularized. Studies were

excluded if the follow-up time was less than 12 months and if studies did not contain original data or data on subjective outcome.

If reported, data on the following outcomes were summarized in Tables: prolapse symptoms or subjective outcome, stress urinary incontinence, overactive bladder, voiding difficulties, anal incontinence, obstructed defecation, dyschezia, pain, and dyspareunia.

Functional outcome: patient-centered

Literature review

Eleven original studies employing transvaginal mesh to treat pelvic organ prolapse were found according to the above-mentioned inclusion and exclusion criteria. However, functional outcomes were irregularly reported (Table 1). There were no studies that provided information explicitly on bowel function.

Questionnaires: symptoms versus scores

Self-administered symptom-specific pelvic floor function and quality of life questionnaires are the gold standard when assessing the patient's perspective after pelvic floor reconstructive surgery [19]. There are several validated questionnaires assessing different or all aspects of pelvic floor dysfunction [20–25]. Especially, the ICI questionnaires (<http://www.iciq.net>) are robust measures of symptoms and quality of life [26]. Although it is to be commended that these questionnaires are increasingly used, the simple report of scores does not necessarily help when counseling women for pelvic floor surgery. The rates of persistent stress urinary incontinence or de novo overactive bladder or dyspareunia also seem very relevant issues to be discussed and presented. This issue is corroborated by one trial on anterior Prolift [27]: Bladder Function Questionnaire scores significantly decreased 12 months after surgery, but 39/57 (68%) had persistent and 9/52 (17%) had de novo stress urinary incontinence [27].

Subjective cure of prolapse symptoms

After trocar-guided transobturator vaginal mesh surgery, symptomatic recurrence of pelvic organ prolapse was reported between 7 and 33%. If analyzed cumulatively, 76 of 370 operated patients (21%) complained of prolapse symptoms postoperatively [28–32]. Still, although 17/36 women in one trial [31] using anterior Prolift to treat recurrent cystocele had stage 2 or more recurrent anterior prolapse after a mean follow-up time of 24 months, most

Table 1 Included studies and their functional outcomes

| Study | Design | Operation | Follow-up months | Inclusion criteria | Subjective failure | SUI | UII | Pain | Sexual function |
|-----------------------|-------------------------|-------------------------------------------------|------------------|-------------------------------------------------------|----------------------|-----------------------------------|----------------------------------------------|-------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| Altman et al. [28] | RCT | Anterior colporrhaphy | 12 | Stage 2+ anterior POP | 66/174 (38%) | De novo SUI 11/176 (6.2%) | | 0 | Pain: 2% Satisfaction: 40% |
| | | Anterior prolift | 12 | Stage 2+ anterior POP | 44/179 (25%) | De novo SUI 22/179 (12.3%) | | 1 (0.5%) | Pain: 7.3% Satisfaction: 48% |
| Maher et al. [30] | RCT | Laparoscopic sacrocolpopexy | 24 | Symptomatic vault prolapse stage 2+ | 1/53 (2%) | Urodynamic SUI: 7 (16%) | | | |
| | | Prolift | 24 | Symptomatic vault prolapse stage 2+ | 4/55 (7%) | Urodynamic SUI: 14 (33%) | | | |
| Milani et al. [29] | Prospective follow-up | Prolift +M | 12 | POP stage III or IV | 8.9% | SUI worsening/de novo: 17 (13.3) | | 5 (3.9%), in 3 pain only elicited during pelvic examination | De novo dyspareunia 1/49 (2.0%) |
| Zyczynski et al. [33] | Prospective follow-up | Proxima | 12 | Symptomatic POP stage 2+ | 14% (n = 130) | | | | De novo dyspareunia 3 |
| Alcalay et al. [37] | Prospective | Trocarless mesh attached near SSL and laterally | 12 | POP | 1/20 (5%) | De novo 2/20 (10%) | 3/20 (15%) | | 2/8 dyspareunia 1/8 device-related Dyspareunia (too medial "fastener") |
| Ek et al. [27] | Prospective follow-up | Anterior prolift | 12 | Stage 2+ anterior POP | 39/57 68% persistent | 39/57 68% persistent | UDI irritative scores improved significantly | UDI pain scores improved significantly | Not reported |
| | | Anterior prolift | 24+ | Recurrent anterior POP | 12/36 (33%) | 32/57 worsend 9/52 de novo 17% | 6 improved 9 unchanged | | 7/16 worsening dyspareunia 5/16 improvement in dyspareunia 6/16 deteriorated coital incontinence |
| Feiner et al. [32] | Prospective follow-up | Prolift + sacrospinous ligament fixation | 12 | Stage 2+ anterior POP, stage 1+ uterine/posterior POP | 84% (84/100) | De novo 2 (2%) | 7 (7%) | Persisting thigh pain 1 | 3 dyspareunia related to mesh contraction |
| Jacquetin et al. [35] | Prospective follow up | Prolift | 36 | Leading edge of POP ≥ -1 cm | | | | | De novo dyspareunia: 5/33 (15%) |
| Moore et al. [34] | Prospective follow-up | Perigee | 24 | Symptomatic stage2+ anterior POP | | | De novo urge incontinence 4/87 (3.5%) | 5 (4.4%): 2 groin/pelvic, 2 vaginal, 1 with sitting | Overall dyspareunia rate post-op: 19/65 (29%) De novo dyspareunia: 6/94 (6.4%), 2 required surgical intervention |
| Long et al. [36] | Retrospective follow-up | Perigee +- SUS | Mean 20 | Stage 2+ anterior POP | | Unclear preop data | Unclear preop data | | De novo or worsened dyspareunia: 10 (17%) |
| | | Anterior Prolift +- SUS | Mean 12 | Stage 2+ anterior POP | | Unclear preop data | Unclear preop data | | De novo or worsened dyspareunia 12 (25%) |

POP pelvic organ prolapse, SUI stress urinary incontinence, UII urge urinary incontinence, RCT randomized controlled trial

women (28/36) considered themselves “very much better” or “much better”. The global impression on improvement did neither correlate with the POPQ nor with dyspareunia nor with mesh erosion [31]. Laparoscopic sacrocolpopexy resulted in considerably less symptomatic prolapse at 2% [30]. In one trial, the trocar-less Proxima system was evaluated demonstrating a 14% symptomatic recurrence rate at 12 months [33].

Urinary incontinence

De novo stress urinary incontinence occurred in 12–17% [28, 31, 32] and persisted in up to 68% [27] after trocar-guided surgery, which is significantly more than after anterior colporrhaphy (6%) in one randomized controlled trial [28].

Although overactive bladder symptoms should be considered a very important outcome, urge incontinence is rarely reported separately. De novo urge incontinence was described in 3.5% after anterior transobturator mesh (Perigee) in one study [34].

Sexual function

Apart from symptoms scores, which usually improve after prolapse surgery, dyspareunia was the only relatively consistently communicated outcome. De novo dyspareunia was present between 2 and 15% [29, 33–35] after transobturator mesh. Some studies described worsened or de novo dyspareunia in 25% [36] and 44% [31]. There was also dyspareunia related specifically to the mesh (mesh contraction [32]) or the mesh attachment device [37]. Deteriorating coital incontinence was described in 6 of 16 women after anterior Prolift [31].

Evidence for or against meshes

The short summary version of the most recent Cochrane review on surgical management of pelvic organ prolapse states: “The inclusion of new randomised controlled trials showed that the use of mesh at the time of anterior vaginal wall repair reduces the risk of recurrent anterior vaginal wall prolapse on examination. However, this was not translated into improved functional or quality of life outcome [17].” Reviews including non-randomized trials are in agreement with this conclusion [11, 19]. For apical support defects, vaginal mesh kits might be beneficial, but mesh-related complications have to be considered [4].

Although data are scarce, the current Cochrane and other reviews including non-randomized trials [11, 17, 38] do not support the use of vaginal mesh in the posterior compartment. Outcomes were not superior to native tissue repairs, neither anatomically nor functionally.

Eminence-based opinions

Most current studies employ modern meshes and established operations. Presently, vaginal mesh kits or self-styled meshes are meant to replace insufficient endopelvic fascia and have arms or anchors to attach them apically, distally, and laterally. They are rarely placed as an overlay in addition to an anterior or posterior repair. A literature review on studies employing self-cut anterior meshes that only provide distal transobturator or arcus tendineous fascia pelvis attachment [39–42] reveals low anatomical success rates between 12 and 36% when compared to mesh kits [3, 4]. Apical and lateral or distal mesh attachment, therefore, seems important rendering armed or anchored mesh applications more successful anatomically. However, mesh arms under tension are responsible for a significant number of dyspareunia. [43] Likewise, anchoring the repaired endopelvic fascia apically to the sacrospinous or uterosacral ligaments may yield better results.

Aptitude and attitudes

Surgeons placing transvaginal mesh should be sufficiently trained and experienced in general pelvic floor surgery. In most areas of life, adequate training is a prerequisite of a success. Surgeon-credentialing efforts are underway (IUGA Grafts Roundtable 2010). However, so far, these are not binding laws, and things are handled differently all over the world. In some countries, urogynecology is a subspecialty, and in others, there are not even scheduled lectures for students at medical schools. There is some evidence showing that surgical skill is associated with success or failure and complications of the procedures [44]. Whether patients should be informed of the case load and personal experience of a surgeon remains debatable. However, informed consent and shared decision-making have to include information on the diagnosis, the planned procedure, its success rates, as well as its risks and complications including further surgery and alternative management, including observation. The simple solution is to have the right attitude toward the patients: information and counseling and risk–benefit estimation taking the surgical skills, the material and the procedure as well as patient-related factors like obesity into account. Figure 1 provides an illustration of factors likely to influence a decision-making process. While the surgeon’s expertise is a combination of knowledge of the diagnosis, etiology, pathogenesis, probable progress with and without treatment, and therapeutical options and outcomes based on experience and scientific data, the patient’s view concerns more the impact of the condition on her daily life, her own risk–benefit estimation, values, and preferences. The more the




Fig. 1 Factors likely to influence the decision-making process

aspects patient, surgeon, and scientific evidence overlap (Fig. 2), the less difficult the decision should be. If we are to take the patient’s concerns and preferences into account, the shared decision-making process might result in easy or comfortable agreements on the best care for this particular patient. The following two examples will illustrate this issue.

Example 1 (Fig. 3): complete uterovaginal eversion, no clinical or occult stress urinary incontinence

Surgical options in various combinations depending on surgeon’s repertoire

- anterior and posterior repair
- paravaginal repair
- sacrospinous fixation, enterocele repair
- uterosacral ligament fixation
- Armed or anchored transvaginal mesh
- Sacrohysteropexy




Fig. 2 The more the surgeon’s and the patient’s views as well as the scientific evidence overlap, the easier the decision-making process should be



Fig. 3 Example 1: Complete uterovaginal eversion, no clinical or occult stress urinary incontinence

- +- hysterectomy, +- anti-stress incontinence procedure
- Sacrocolpopexy after hysterectomy, +- prophylactic Burch colposuspension

Data

Sacrocolpopexy may provide best anatomical results [1], but concomitant hysterectomy may increase the risk for erosion [30, 45, 46]. The risk for erosion may also apply for vaginal mesh placement, although data for both procedures are ambiguous [47–49]. Vaginal sacrospinous fixation with or without hysterectomy offers a good chance of success [1, 50], especially with the placement of anterior mesh [32]. Uterine preservation is a viable option [1, 50–52].

Patient’s choice #1

- Spinal anesthesia → vaginal or open abdominal procedure
- Preference no abdominal incision → vaginal surgery
- Desire to have sexual intercourse without intractable pain → omit vaginal mesh placement and levator plication
- Prefers to keep uterus as asymptomatic → vaginal hysteropexy
- Prefers risk of recurrence over risk of pain syndrome → omit vaginal mesh and levator plication

→ Vaginal sacrospinous hysteropexy, anterior and posterior fascial repair.

Patient’s choice #2

- Prefers risk of pain syndrome or mesh erosion over recurrence, would like to minimize risk to ever require further pelvic organ prolapse surgery → mesh placement possible
- Desires hysterectomy including bilateral salpingo-oophorectomy because of fear of cancer as sister has

breast cancer → vaginal or laparoscopic or open abdominal hysterectomy with BSO

- Prefers laparoscopic over open procedure and over vaginal approach to safely remove ovaries
- Obstructed defecation symptoms bothersome → vaginal rectocele repair

→ Laparoscopic hysterectomy and bilateral salpingo-oophorectomy, sacrocolpopexy using polypropylene mesh, posterior repair for low rectocele.

Example 2 (Fig. 4): anterior vaginal wall and uterine prolapse stage 2 with stress urinary incontinence, small rectocele (stage 1).

Surgical options in various combinations depending on surgeon's repertoire

- Anterior repair
- Paravaginal repair
- Sacrospinous fixation
- Uterosacral ligament fixation
- Armed or anchored transvaginal mesh
- Sacrohysteropexy
- +/- Hysterectomy
- Sacrocolpopexy after hysterectomy

Data

The review of RCT's on anterior vaginal wall prolapse demonstrated lower anatomical failure rates when transvaginal meshes are used [1]. However, native tissue repair is feasible, especially in a primary prolapse [1, 17, 53]. Although the Cochrane review did not support concomitant stress incontinence procedures, the insertion of a suburethral tape at the time of an anterior repair improved postoperative continence rates [1, 17]. As in Example 1, uterine preservation is a viable option in selected patients [51, 54]. Laparoscopic Burch colposuspension provides similar

success rates compared to suburethral tapes if performed by an experienced surgeon [55].

Patient's view #1

- Preservation of sexual sensitivity (wish for G-spot sparing surgery) → avoid vaginal surgery
- Prefers preservation of the uterus → laparoscopic or open abdominal hysteropexy
- Prefers laparoscopy over abdominal incision
- Stress urinary incontinence bothersome, prefers concomitant procedure → Burch colposuspension as suburethral tape might interfere with sensible vaginal tissue (G-spot)

→ Laparoscopic Burch colposuspension, paravaginal repair, and sacrohysteropexy using mesh.

Patient's view #2

- Prefers enhancement of sexual sensitivity by narrowing vaginal diameter → posterior repair
- Prefers risk of pain syndrome or mesh erosion over recurrence, would like to minimize risk to ever require further pelvic organ prolapse surgery → mesh insertion an option
- Is afraid of adductor muscle injury/necrotizing fasciitis → avoid transobturator mesh
- Desires hysterectomy without bilateral salpingo-oophorectomy to reduce risk of uterine cancer, but keep ovaries because of ongoing testosterone production

→ Vaginal hysterectomy and high uterosacral ligament vault fixation, posterior repair, anterior vaginal mesh with attachment at sacrospinous ligaments, and arcus tendineus fascial pelvis.

Conclusion

In selected cases, we do need meshes in vaginal reconstructive surgery. However, the selection process is not all clear. There are some factors that deem the use of transvaginal mesh possibly to be beneficial as far as anatomical outcome is concerned: previous failed pelvic floor surgery, large prolapse, obesity, chronic pelvic floor stress (e.g., asthma), deficient connective tissue, and a combination of these factors. Regarding function, this short review demonstrated a high cumulative subjective failure rate of 21%, which appears considerably lower than promising reports on anatomical success. Although this review was unable to provide new information, the stated rates of recurrent prolapse symptoms as well as dyspareunia might be helpful when counseling women. Worsening or de novo



Fig. 4 Example 2: Anterior vaginal wall and uterine prolapse stage 2 with stress urinary incontinence

dyspareunia rates as high as 44% appear disturbing. Also, coital incontinence was found to have deteriorated in 37% [31]. There was only this one study reporting this very common and bothersome symptom. However, the impact of these symptoms on the women's quality of life has not been assessed in these trials.

The most important contributor to the decision-making process is the informed patient. A large proportion of the current discussion on vaginal meshes appears redundant if we would regard the woman with pelvic organ prolapse a collaborator to reach the ultimate goal: reconstructive surgery that results in best possible pelvic floor anatomy and function.

Conflict of interest No conflicts of interest, no disclosures.

References

1. Maher C, Feiner B, Baessler K, Adams EJ, Hagen S and Glazener CM (2010) Surgical management of pelvic organ prolapse in women. *Cochrane Database Syst Rev* 14:CD004014
2. Sentilhes L, Descamps P, Marpeau L (2009) Graft use in transvaginal pelvic organ prolapse repair: a systematic review. *Obstet Gynecol* 113:952 author reply 952
3. Moore RD, Miklos JR (2009) Vaginal mesh kits for pelvic organ prolapse, friend or foe: a comprehensive review. *Sci World J* 9:163–189
4. Feiner B, Jelovsek JE, Maher C (2009) Efficacy and safety of transvaginal mesh kits in the treatment of prolapse of the vaginal apex: a systematic review. *BJOG* 116:15–24
5. Diwadkar GB, Barber MD, Feiner B, Maher C, Jelovsek JE (2009) Complication and reoperation rates after apical vaginal prolapse surgical repair: a systematic review. *Obstet Gynecol* 113:367–373
6. Sung VW, Rogers RG, Schaffer JI, Balk EM, Uhlig K, Lau J, Abed H, Wheeler TL 2nd, Morrill MY, Clemons JL, Rahn DD, Lukban JC, Lowenstein L, Kenton K, Young SB (2008) Graft use in transvaginal pelvic organ prolapse repair: a systematic review. *Obstet Gynecol* 112:1131–1142
7. Nguyen JN (2008) The use of grafts for anterior vaginal prolapse repair: pros and cons. *Curr Opin Obstet Gynecol* 20:501–505
8. Jakus SM, Shapiro A, Hall CD (2008) Biologic and synthetic graft use in pelvic surgery: a review. *Obstet Gynecol Surv* 63:253–266
9. De Ridder D (2008) Should we use meshes in the management of vaginal prolapse? *Curr Opin Urol* 18:377–382
10. South M, Amundsen CL (2007) Pelvic organ prolapse: a review of the current literature. *Minerva Ginecol* 59:601–612
11. Jia X, Glazener C, Mowatt G, MacLennan G, Bain C, Fraser C, Burr J (2008) Efficacy and safety of using mesh or grafts in surgery for anterior and/or posterior vaginal wall prolapse: systematic review and meta-analysis. *BJOG* 115:1350–1361
12. Zimmerman CW, Sheth SS (2011) Anterior, posterior and apical vaginal reconstruction with and without bolsters. *Best Pract Res Clin Obstet Gynaecol* 25:167–174
13. Gomelsky A, Penson DF, Dmochowski RR (2011) Pelvic organ prolapse (POP) surgery: the evidence for the repairs. *BJU Int* 107:1704–1719
14. Morrisroe S, Lee U, Raz S (2011) The use of mesh in vaginal prolapse repair: do the benefits justify the risks? *Curr Opin Urol* 20:275–279
15. McIntyre M, Goudelocke C, Rovner ES (2011) An update on surgery for pelvic organ prolapse. *Curr Opin Urol* 20:490–494
16. Baessler K, Maher CF (2006) Mesh augmentation during pelvic-floor reconstructive surgery: risks and benefits. *Curr Opin Obstet Gynecol* 18:560–566
17. Maher CM, Feiner B, Baessler K, Glazener CM (2011) Surgical management of pelvic organ prolapse in women: the updated summary version Cochrane review. *Int Urogynecol J* 22:1445–1457
18. Baessler K, O'Neill S, Maher C (2006) Prevalence, incidence, progression and regression of pelvic organ prolapse in a community cohort: results of a 5-year longitudinal study. *Neurourol Urodynam* 25:520–522
19. Staskin D et al (2009) Patient-reported outcome assessment. In: Abrams P, Cardozo L, Khoury S, Wein A (eds) *Incontinence*, 4th edn. Health Publication Ltd, Paris
20. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S (1997) A new questionnaire to assess the quality of life of urinary incontinent women. *Br J Obstet Gynaecol* 104:1374–1379
21. Baessler K, O'Neill SM, Maher CF, Battistutta D (2009) Australian pelvic floor questionnaire: a validated interviewer-administered pelvic floor questionnaire for routine clinic and research. *Int Urogynecol J Pelvic Floor Dysfunct* 20:149–158
22. Barber MD, Kuchibhatla MN, Pieper CF, Bump RC (2001) Psychometric evaluation of 2 comprehensive condition-specific quality of life instruments for women with pelvic floor disorders. *Am J Obstet Gynecol* 185:1388–1395
23. Jackson S, Donovan J, Brookes S, Eckford S, Swithinbank L, Abrams P (1996) The bristol female lower urinary tract symptoms questionnaire: development and psychometric testing. *Br J Urol* 77:805–812
24. Shumaker SA, Wyman JF, Uebersax JS, McClish D, Fantl JA (1994) Health-related quality of life measures for women with urinary incontinence: the incontinence impact questionnaire and the urogenital distress inventory. Continence program in women (CPW) research group. *Qual Life Res* 3:291–306
25. Kammerer-Doak D (2009) Assessment of sexual function in women with pelvic floor dysfunction. *Int Urogynecol J Pelvic Floor Dysfunct* 20(Suppl 1):S45–S50
26. Abrams P, Avery K, Gardener N and Donovan J (2006) The International Consultation on Incontinence Modular Questionnaire: <http://www.icq.net>. *J Urol* 175:1063–1066 (discussion 1066)
27. Ek M, Altman D, Falconer C, Kulseng-Hanssen S, Tegerstedt G (2010) Effects of anterior trocar guided transvaginal mesh surgery on lower urinary tract symptoms. *Neurourol Urodyn* 29:1419–1423
28. Altman D, Vayrynen T, Engh ME, Axelsen S, Falconer C (2011) Anterior colporrhaphy versus transvaginal mesh for pelvic-organ prolapse. *N Engl J Med* 364:1826–1836
29. Milani AL, Hinoul P, Gauld JM, Sikirica V, van Drie D, Cosson M (2011) Trocar-guided mesh repair of vaginal prolapse using partially absorbable mesh: 1 year outcomes. *Am J Obstet Gynecol* 204:74 e1–74 e8
30. Maher C, O'Rourke P (2011) Trocar-guided mesh compared with conventional vaginal repair in recurrent prolapse: a randomized controlled trial. *Obstet Gynecol* 117:1435–1436 author reply 1436–1437
31. Fayyad AM, North C, Reid FM, Smith AR (2010) Prospective study of anterior transobturator mesh kit (prolift) for the management of recurrent anterior vaginal wall prolapse. *Int Urogynecol J* 22:157–163
32. Feiner B, Gietelink L, Maher C (2010) Anterior vaginal mesh sacrospinous hysteropexy and posterior fascial plication for anterior compartment dominated uterovaginal prolapse. *Int Urogynecol J* 21:203–208

33. Zyczynski HM, Carey MP, Smith AR, Gauld JM, Robinson D, Sikirica V, Reisenauer C, Slack M (2011) One-year clinical outcomes after prolapse surgery with nonanchored mesh and vaginal support device. *Am J Obstet Gynecol* 203:587 e1–587 e8
34. Moore RD, Beyer RD, Jacoby K, Freedman SJ, McCammon KA, Gambla MT (2010) Prospective multicenter trial assessing type I, polypropylene mesh placed via transobturator route for the treatment of anterior vaginal prolapse with 2-year follow-up. *Int Urogynecol J* 21:545–552
35. Jacquetin B, Fatton B, Rosenthal C, Clave H, Debodinance P, Hinoul P, Gauld J, Garbin O, Berrocal J, Villet R, Salet Lizee D, Cosson M (2010) Total transvaginal mesh (TVM) technique for treatment of pelvic organ prolapse: a 3-year prospective follow-up study. *Int Urogynecol J* 21:1455–1462
36. Long CY, Hsu CS, Jang MY, Liu CM, Chiang PH, Tsai EM (2010) Comparison of clinical outcome and urodynamic findings using “Perigee and/or Apogee” versus “Prolift anterior and/or posterior” system devices for the treatment of pelvic organ prolapse. *Int Urogynecol J* 22:233–239
37. Alcalay M, Cosson M, Livneh M, Lucot JP, Von Theobald P (2010) Trocarless system for mesh attachment in pelvic organ prolapse repair—1-year evaluation. *Int Urogynecol J* 22:551–556
38. Kudish BI, Iglesia CB (2011) Posterior wall prolapse and repair. *Clin Obstet Gynecol* 53:59–71
39. de Tayrac R, Devoldere G, Renaudie J, Villard P, Guilbaud O, Eglin G (2007) Prolapse repair by vaginal route using a new protected low-weight polypropylene mesh: 1-year functional and anatomical outcome in a prospective multicentre study. *Int Urogynecol J Pelvic Floor Dysfunct* 18:251–256
40. Milani AL, Heidema WM, van der Vloedt WS, Kluivers KB, Withagen MI, Vierhout ME (2008) Vaginal prolapse repair surgery augmented by ultra lightweight titanium coated polypropylene mesh. *Eur J Obstet Gynecol Reprod Biol* 138:232–238
41. Letouzey V, Deffieux X, Gervaise A, Mercier G, Fernandez H, de Tayrac R (2010) Trans-vaginal cystocele repair using a tension-free polypropylene mesh: more than 5 years of follow-up. *Eur J Obstet Gynecol Reprod Biol* 151:101–105
42. Hung MJ, Liu FS, Shen PS, Chen GD, Lin LY, Ho ES (2004) Factors that affect recurrence after anterior colporrhaphy procedure reinforced with four-corner anchored polypropylene mesh. *Int Urogynecol J Pelvic Floor Dysfunct* 15:399–406 discussion 406
43. Feiner B, Maher C (2010) Vaginal mesh contraction: definition, clinical presentation, and management. *Obstet Gynecol* 115:325–330
44. Ahtari C, Hiscock R, O’Reilly BA, Schierlitz L, Dwyer PL (2005) Risk factors for mesh erosion after transvaginal surgery using polypropylene (Atrium) or composite polypropylene/polyglactin 910 (Vypro II) mesh. *Int Urogynecol J Pelvic Floor Dysfunct* 16:389–394
45. Wu JM, Wells EC, Hundley AF, Connolly A, Williams KS, Visco AG (2006) Mesh erosion in abdominal sacral colpopexy with and without concomitant hysterectomy. *Am J Obstet Gynecol* 194:1418–1422
46. Tan-Kim J, Menefee SA, Lubber KM, Nager CW, Lukacz ES (2011) Prevalence and risk factors for mesh erosion after laparoscopic-assisted sacrocolpopexy. *Int Urogynecol J* 22:205–212
47. Ganj FA, Ibeanu OA, Bedestani A, Nolan TE, Chesson RR (2009) Complications of transvaginal monofilament polypropylene mesh in pelvic organ prolapse repair. *Int Urogynecol J Pelvic Floor Dysfunct* 20:919–925
48. Nosti PA, Lowman JK, Zollinger TW, Hale DS, Woodman PJ (2009) Risk of mesh erosion after abdominal sacral colpopexy with concomitant hysterectomy. *Am J Obstet Gynecol* 201:541 e1–544 e1
49. Brizzolara S, Pillai-Allen A (2003) Risk of mesh erosion with sacral colpopexy and concurrent hysterectomy. *Obstet Gynecol* 102:306–310
50. Maher CF, Cary MP, Slack MC, Murray CJ, Milligan M, Schluter P (2001) Uterine preservation or hysterectomy at sacrospinous colpopexy for uterovaginal prolapse? *Int Urogynecol J Pelvic Floor Dysfunct* 12:381–384 discussion 384–385
51. Diwan A, Rardin CR, Kohli N (2004) Uterine preservation during surgery for uterovaginal prolapse: a review. *Int Urogynecol J Pelvic Floor Dysfunct* 15:286–292
52. Diwan A, Rardin CR, Strohsnitter WC, Weld A, Rosenblatt P, Kohli N (2006) Laparoscopic uterosacral ligament uterine suspension compared with vaginal hysterectomy with vaginal vault suspension for uterovaginal prolapse. *Int Urogynecol J Pelvic Floor Dysfunct* 17:79–83
53. Maher C, Baessler K (2006) Surgical management of anterior vaginal wall prolapse: an evidencebased literature review. *Int Urogynecol J Pelvic Floor Dysfunct* 17:195–201
54. Maher CF, Carey MP, Murray CJ (2001) Laparoscopic suture hysteropexy for uterine prolapse. *Obstet Gynecol* 97:1010–1014
55. Jelovsek JE, Barber MD, Karram MM, Walters MD, Paraiso MF (2008) Randomised trial of laparoscopic Burch colposuspension versus tension-free vaginal tape: long-term follow up. *BJOG* 115:219–225 discussion 225